Phreesia's Partnership with CMS Enhances Kidney Care Outcomes
Phreesia's Continued Commitment to Kidney Care Innovation
Phreesia, a frontrunner in patient activation technology, is thrilled to announce the renewal of its contract with the CMS Innovation Center (CMMI) through 2029. This collaboration focuses on enhancing patient engagement through the Patient Activation Measure (PAM), which evaluates how well patients understand, feel empowered, and manage their own healthcare. PAM is pioneering in that it is one of the earliest performance measures derived from patient-reported outcomes within the CMS alternative payment models.
Enhancing Patient Outcomes in Kidney Care
Since 2019, Phreesia has been a key partner in the CMMI’s Kidney Care Choices Model (KCC) aimed at benefiting nearly 200,000 Medicare beneficiaries suffering from chronic kidney disease (CKD). The KCC Model promotes early intervention to delay dialysis and encourages home dialysis while incentivizing kidney transplants to enhance patient quality of life.
Success Metrics from the KCC Evaluation
With the first annual evaluation of the KCC model recently published, substantial positive outcomes have been highlighted: an average increase of 8.8 PAM points across various patient groups, notably the 12.8-point surge among transplant patients. Such improvements are tied to potential reductions in healthcare costs by up to 8% as shown in earlier studies.
Targeted Improvements and Continued Growth
The KCC program has significantly outstripped previous kidney care interventions, doubling the typical score improvements in patient activation. Metrics indicate a notable 20% upswing in home dialysis, as well as between 8% to 26% in peritoneal dialysis rates. Furthermore, the number of patients on the transplant waitlist rose by 15%, demonstrating broader engagement and activation amongst participants.
Phreesia's Role in Driving Patient Activation
“We are honored to partner with CMMI and KCC participants in improving kidney care outcomes,” stated Hilary Hatch, PhD, Phreesia’s Chief Clinical Officer. “The first year of KCC showed remarkable surges in PAM scores reflecting how many kidney patients are taking charge of their health. As CMMI implements more patient-reported measures, we are enthusiastic about extending PAM access for diverse conditions and care environments.”
The Power of Patient Activation Measurement
The foundation of the PAM rests on robust evidence from over 800 peer-reviewed studies, affirming its ability to predict health behaviors linked to improved outcomes in patient care. An increase in patient activation is correlated with better clinical results, medication adherence, self-management of diseases, and overall satisfaction with treatment plans.
Endorsements and Future Directions
As Alan Glaseroff, MD, renowned co-founder of Stanford Coordinated Care suggests, the year one outcomes from KCC are groundbreaking. The model’s focus on clinician incentives leads to profound patient engagement, uncovering a pathway reminiscent of successes seen in prior initiatives. This continual evolution of care practices is likely to further lower expenses while enhancing patient health outcomes in subsequent years.
Looking Ahead: Phreesia's Impact
Phreesia remains dedicated to its mission of enabling healthcare providers to empower their patients. By facilitating tools for patient activation, education, and outreach, the company is poised to transform healthcare experiences. The scale of Phreesia’s operations—supporting 150 million patient visits in a recent year—highlights its ability to create meaningful change across the healthcare landscape.
Frequently Asked Questions
1. What is the primary objective of Phreesia's partnership with CMS?
The partnership focuses on enhancing patient activation and improving healthcare outcomes for kidney disease patients using the Patient Activation Measure (PAM).
2. How has the KCC model benefitted patients?
The KCC model aims to improve care for CKD patients by incentivizing preventive measures and facilitating improved patient engagement, thus enhancing their quality of life.
3. What significant findings emerged from the KCC evaluation?
The evaluation found notable increases in PAM scores and improvements in care metrics, including a surge in home dialysis rates and better patient activation across all demographics.
4. How does PAM contribute to patient outcomes?
PAM helps evaluate patient knowledge and confidence, leading to improved adherence, self-management, and higher satisfaction with care received.
5. What future developments are anticipated for Phreesia and CMMI?
Both organizations aim to expand PAM’s application to more models and conditions, continually improving patient activation efforts across various healthcare settings.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Thrive Causemetics Supports Awareness with New Product Launch
- Revolutionizing DeFi: Glue Network Enhances Access with Banxa
- Treasury Wine Estates Teams Up with Hello Sunshine for New Wines
- Kohler Partners with Remedy Place to Transform Home Wellness
- Transforming Aviation with More Electric Aircraft Innovations
- First American Financial: Safeguarding Real Estate with Title Insurance
- Color Star Achieves Nasdaq Compliance with Share Price Rule
- Atar Capital's Solero Technologies Expands with Kendrion Deal
- Petra Funds Group Expands Team with Key Leadership Roles
- Innovative Career Solutions Drive EdTech Forward with AI
Recent Articles
- Elon Musk Critiques FCC's Denial of Starlink Subsidy While Aiding Disaster Recovery
- Tenet Healthcare Corporation Finalizes Sale of Hospital Network
- Tradr ETFs Unveils First Quarterly Reset Leveraged ETFs
- Silexion Therapeutics Advances SIL-204 with New Findings
- Stock Market Sees Gains Despite High Volatility and Earnings Ahead
- McCormick Sees Steady Growth Amid Economic Challenges
- McCormick Surpasses Expectations with Strong Q3 Performance
- JPMorgan Boosts Coterra Energy's Price Target to $28
- Premier Inc. Expands Investment in Prestige Ameritech for Growth
- Acadia Realty Trust Boosts Share Offering for Future Growth
- McCormick & Company Reflects on Strong Q3 Performance
- Shattuck Labs Transitions to Focus on SL-325 After SL-172154 Shift
- GFL Environmental Inc. Secures $210 Million in Revenue Bonds
- Bionomics' Strategic Shift: U.S. Re-Domiciliation for Growth
- McCormick Reports Strong Earnings and Positive Future Guidance
- Barclays Raises Price Target for monday.com Amid Growth
- Exploring Incyte's Stock Outlook and Future Potential
- Lion Electric Enhances Liquidity with Credit Agreement Adjustments
- IGM Biosciences Charts New Course Focused on Autoimmune Therapies
- Unlocking Tesla's Future: AI, Innovation, and Growth Strategies
- Bitcoin's Resilience Shines Amid Market Volatility Ahead of October
- Pharmanovia's Chloral Hydrate Study Offers Hope for Insomnia Sufferers
- BJ's Wholesale Club Unveils Best Toys for Holiday Shopping
- Nextdoor's Treat Map Returns for Another Spooktacular Season
- SHI International Enhances Global Reach with Locuz Acquisition
- Verizon's Strategic Moves to Enhance Financial Stability in Telecom
- Stevanato Group Unveils Advanced 10mL Delivery System at CPHI
- Top High-Yield Dividend Stocks to Buy This Month
- Merck Announces Third-Quarter Earnings Call for 2024
- Henry Schein Plans Live Earnings Call for Quarter 2024 Results
- Sitio Royalties Enhances Transparency with Q3 Earnings Call
- Label Printers Market Set for Growth: Key Drivers and Trends
- Avery Dennison Prepares for Q3 2024 Earnings Call Discussion
- Autonomous Mobile Robots: Rapid Market Growth Forecast Ahead
- SITE Centers Completes Strategic Spin-Off of Curbline Properties
- Future of Self-Contained Breathing Apparatus Market Growth
- Sovos Unveils Innovative Indirect Tax Suite Tailored for SAP
- Shattuck Labs Advances New DR3 Antagonist, SL-325, for IBD
- Bionomics Limited Plans Move to the U.S. for Growth
- USALLIANCE Financial and MarkIII Team Up to Enhance Lending
- Hut 8 Successfully Transforms Loan Into Common Shares
- Market Anticipates Labor Data Amid Powell's Rate Insights
- Infinedi's CEA CAPA Education Abroad Expands With Atlantis
- Hut 8 Successfully Converts $38 Million Loan into Equity Stake
- Daily Market Rundown: Nifty 50 & Other Major Indices
- Prospect Partners Achieves Major Milestone with Fund V Closure
- Acuity Brands Surprises with Strong Q4 Earnings and Growth
- Premier, Inc. Expands Stake in PPE Sector with Prestige Ameritech
- Tesla's Swedish Market Growth Amid Ongoing Labor Dispute
- Acadia Realty Trust Sets Price for Significant Share Offering